Influence of some statins on bacteria and actinomyces

• Autorzy: Targonski R. , Kucharski, J. , Wyszkowska J.

Warianty tytułu

PL

Wpływ niektórych statyn na bakterie i promieniowce

• Języki publikacji: EN

Abstrakty

EN

In an in uitro experiment the effect of three statins (atorvastatin [Sortis], simvastatin [Zocor], fluvastatin [Lescol]) on the growth of 5 bacterial strains Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli and 4 saprophytic actinomycetes Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis was tested. The experiments were carried out on solidified substrata with microorganisms covered with filter paper rings soaked with aqueous solution of every tested statin used in different concentrations. It was found that examined substances can inhibit the growth of certain saprophytic microorganisms. Fluvastatin rather than simvastatin or atorvastatin produces stronger effect on bacteria and actinomycetes.

PL

W doświadczeniu in vitro badano wpływ trzech statyn (atorwastatyny [Sortis], simwastatyny [Zocor], fluwastatyny [Lescol]) na rozwój 5 szczepów bakterii: Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli oraz 4 saprofitycznych promieniowców: Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis. Doświadczenia prowadzono na zestalonych podłożach, przy czym mikroorganizmy przykrywano krążkami papieru filtrującego, nasączonymi wodnym roztworem poszczególnych statyn w różnych stężeniach. Stwierdzono, że badane substancje mogą ograniczać rozwój pewnych mikroorganizmów saprofitycznych. Fluwastatyna miała silniejszy wpływ hamujący na bakterie i promienowce niż simwastatyna lub atorwastatyna.

Słowa kluczowe

EN

atorvastatin; bacteria; statin; simvastatin; fluvastatin; Bacillus subtilis; Bacillus cereus; Proteus vulgaris; Pseudomonas fluorescens; Escherichia coli; actinomycete

• Wydawca: -
• Czasopismo: Journal of Elementology
• Rocznik: 2006
• Tom: 11
• Numer: 4
• Opis fizyczny: p.513-519,fig.,ref.

Twórcy

autor

Targonski R.

• Urban Hospital Cardiology Department in Olsztyn, Olsztyn, Poland

autor

Kucharski, J.

• Chair of Microbiology, University of Warmia and Mazury in Olsztyn, Plac Łodzki 3, 10-727 Olsztyn, Poland

autor

Wyszkowska J.

Bibliografia

• Almog Y., Shefer A., Novack V., Maimon N., Barski L., Eizinger M., Friger M., Zeller L., Danon A. 2004. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation., 110(7): 880-885.
• Barabasz W. 2002. Bioróżnorodność mikroorganizmów w środowiskach glebowych. W: Rola drobnoustrojów w kształtowaniu środowiska. UWM Olsztyn, 16-18.
• Bonetti P.O., Lerman L.O., Napoli C., Lerman A. 2003. Statin effects beyond lipid lowering - are they clinically relevant? Eur. Heart J., 24(3): 225-248.
• Cannon C.P., Braunwald E., McCabe C.H., Grayston J.T., Muhlestein B., Giugliano R.P., Cairns R., Skene A.M. 2005. Pravastatin or Atoruastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med. 352(16):1646-1654.
• Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P. 2003. Effect of short-term treatment with azithromycin on recurrent ischaemic euents in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet., 361(9360): 809-813.
• Davignon J, Ganz P. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation., 109(23 Suppl 1): III 27-32.
• Fernandez R., De Pedro V.J., Artigas A. 2006. Statin therapy prior to ICU admission: protection against infection or a seuerity marker? Intensive Care Med., 32(1):160-164.
• Hackam D.G., Mamdani M., Li P., Redelmeier D.A. 2006. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet., 367(9508): 413-418.
• Kinlay S., Schwartz G.G., Olsson A.G., Rifai N., Leslie S.J., Sasiela W.J., Szarek M., Libby P., Ganz P. 2003. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation., 30 108(13): 1560-1566.
• O'Connor C.M., Dunne M.W., Pfeffer M.A., Muhlestein J.B., Yao L., Gupta S., Benner R.J., Fisher M.R., Cook T.D. 2003. Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA, 290(11):1459-1466.
• Parkinson D., Gray F.R.G., Williams S.T., 1971. Methods for studying the ecology of soil micro-organism. Blackweel Sc. Pub. Oxford and Edinburgh, IBP Handbook, 19.
• Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E. 2005. Pravastatin or Atomastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactwe protein levels and outcomes after statin therapy. N Engl J Med., 352(1): 20-28.
• Rouleau J. 2005. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atonastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am. J. Med. 118 Suppl 12A:28-35.
• Saikku P. 2000. Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more. Infect Dis J., 181 Suppl., 3: 411-413.
• Sinisalo J., Mattila K., Valtonen V., Anttonen O., Juvonen J., Melin J., Vuorinen-Markkola H., Nieminen M.S. 2002. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation., 105(13):1555-1560.
• Sipahi I., Tuzcu E. M., Schoenhagen P., Nicholls S.J., Ozduran V., Kapadia S., Nissen S.E. 2006. Compensatory enlargement of human coronary arteries during progression of atherosclerosis is unrelated to atheroma burden: serial intravascular ultrasound observations from the REVERSAL trial. Eur Heart J., 27(14): 1664-1670.
• Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. 2004. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med., 351(25): 2611-2618.
• Statsoft, Inc. 2003. STATISTICA (data analysis software system), version 6.0. www.statsoft.com.
• Stone A.F., Mendall M.A., Kaski J.C., Edger T.M., Risley P., Poloniecki J., Camm A.J., Northfield T.C. 2002. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMI- NA). Circulation., 106(10): 1219-1223.